Norrin Tag

Data presented on promising activity of Noregen™, first potential regenerative therapy for retinal diseasesFollows 1Q2022 U.S. FDA and EU EMA Orphan Drug Designation (ODD) for Noregen™ in Familial Exudative Vitreoretinopathy (FEVR)    May 3, 2022, Denver, CO and Rochester, MI – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company...

Disorders of vascular structure and function play a central role in a wide variety of CNS diseases. Mutations in the Frizzled4 (Fz4) receptor, Lrp5 co-receptor, or Norrin ligand cause retinal hypovascularization, but the role of Norrin/Fz4/Lrp signaling in vascular development has not been defined. ...